# NKTR catalysts: NEKTAR THERAPEUTICS PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nktr/catalysts

> NEKTAR THERAPEUTICS (NKTR) has 6 upcoming catalysts. The next is the rezpegaldesleukin trial start, Dec 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | NEKTAR THERAPEUTICS |
| Ticker | NKTR (Nasdaq) |
| SEC CIK | 906709 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/nktr |

## Cash runway

Cash $952.9M as of 2026-09-30; quarterly burn $71.9M; about 39.7 months of runway at that rate (XBRL company facts, accession 0001193125-26-458868).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2023 | [Rezpegaldesleukin trial start](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | moderate-to-severe atopic dermatitis | completed | "In October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis (the Phase 2b RESOLVE-AD trial), which is ongoing." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/906709/000119312526349805/nktr-20260630.htm)) |
| Mar 2024 | [Rezpegaldesleukin trial start](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | severe-to-very severe alopecia areata | completed | "In March 2024, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata (the Phase 2b RESOLVE-AA trial)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm)) |
| 1H 2025 | [NEKTAR THERAPEUTICS topline data readout](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | scheduled | "We expect to receive topline data from this study in the first half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/906709/000095017025067279/nktr-20250331.htm)) |
| 1H 2025 | [Rezpegaldesleukin topline data readout](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | moderate-to-severe atopic dermatitis | scheduled | "In October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis, which remains on track for a topline data readout in the first half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/906709/000095017025067279/nktr-20250331.htm)) |
| 2025 | [Rezpegaldesleukin trial start](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR |  | scheduled | "As a result of the data from our Phase 2b RESOLVE-AD trial, we expect research and development expense for rezpegaldesleukin for full year 2025 to increase as compared to 2024, as we commence certain activities to support a Phase 3 trial for this program." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/906709/000119312525270230/nktr-20250930.htm)) |
| March 12, 2025 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390025023220/ea023406001ex99-1_nektar.htm)) |
| May 6, 2025 | [Rezpegaldesleukin primary completion](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Moderate to Severe Atopic Dermatitis | completed | "NCT06136741 (A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-06 (ACTUAL); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06136741)) |
| May 8, 2025 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390025041085/ea0241353ex99-1_nektar.htm)) |
| Q3 2025 | [NEKTAR THERAPEUTICS topline data readout](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | scheduled | "We expect to receive topline data from this study in the third quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/906709/000095017025105275/nktr-20250630.htm)) |
| August 7, 2025 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS"" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390025073100/ea025218301ex99-1_nektar.htm)) |
| November 6, 2025 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390025107180/ea026426101ex99-1_nektar.htm)) |
| November 26, 2025 | [Rezpegaldesleukin primary completion](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Alopecia Areata | completed | "NCT06340360 (A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-26 (ACTUAL); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06340360)) |
| Dec 2025 | [Rezpegaldesleukin topline data readout](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | severe-to-very severe alopecia areata | scheduled | "The Company expects to report full 52-week data from the RESOLVE-AD trial in early 2026 and expects top-line Phase 2b data for rezpegaldesleukin in alopecia areata in the fourth quarter of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/906709/000121390025056909/ea0246672-8k_nektar.htm)) |
| March 12, 2026 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390026027026/ea028133401ex99-1.htm)) |
| Apr 2026 | [Rezpegaldesleukin topline data readout](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | severe-to-very-severe alopecia areata with continued twice-monthly dosing | completed, positive | "In April 2026, Nektar announced positive 52-week topline results from the 16-week blinded treatment extension of the Phase 2b REZOLVE-AA study, demonstrating deepening of responses to rezpegaldesleukin in patients with severe-to-very-severe alopecia areata with continued twice-monthly dosing." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390026089137/ea030192901ex99-1.htm)) |
| Q2 2026 | [Rezpegaldesleukin trial start](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR |  | scheduled | "The Company plans to start the Phase 3 trials in the second quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/906709/000119312526043755/d103279d8k.htm)) |
| May 7, 2026 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2026 RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390026053369/ea028961101ex99-1.htm)) |
| August 13, 2026 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS SECOND QUARTER 2026 RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390026089137/ea030192901ex99-1.htm)) |
| November 12, 2026 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2026 RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390026118964/ea031199801ex99-1.htm)) |
| Dec 2026 | [Rezpegaldesleukin trial start](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR |  | scheduled | "We intend to initiate a global registrational trial (ZENITH AA-1) in December 2026 to evaluate rezpegaldesleukin in patients who are 12 years of age or older with severe-to-very-severe alopecia areata." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/906709/000119312526458868/nktr-20260930.htm)) |
| mid-2028 | [Rezpegaldesleukin interim data readout](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR |  | scheduled | "Initial topline data from the ZENITH AD program are expected in mid-2028, with a BLA submission targeted for 2029." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390026118964/ea031199801ex99-1.htm)) |
| May 2028 | [Rezpegaldesleukin primary completion](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Moderate-to-Severe Atopic Dermatitis | scheduled | "NCT07690371 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07690371)) |
| May to Aug 2028 | [Rezpegaldesleukin topline data readout](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Moderate-to-Severe Atopic Dermatitis | scheduled | "NCT07690371 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07690371)) |
| June 2028 | [Rezpegaldesleukin primary completion](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Moderate-to-Severe Atopic Dermatitis | scheduled | "NCT07711418 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07711418)) |
| Jun to Sep 2028 | [Rezpegaldesleukin topline data readout](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR | Moderate-to-Severe Atopic Dermatitis | scheduled | "NCT07711418 (A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Nektar Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07711418)) |

## Drugs

- [Rezpegaldesleukin](https://sec-api.dev/pdufa/rezpegaldesleukin): moderate-to-severe atopic dermatitis, severe-to-very severe alopecia areata, severe-to-very-severe alopecia areata with continued twice-monthly dosing, alopecia areata in december of this year, Moderate to Severe Atopic Dermatitis, Alopecia Areata

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nktr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NKTR catalysts: NEKTAR THERAPEUTICS PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nktr/catalysts

```bibtex
@misc{secapidev_companies_nktr_catalysts_20261116,
  title        = {NKTR catalysts: NEKTAR THERAPEUTICS PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nktr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nktr_catalysts_20261116","title":"NKTR catalysts: NEKTAR THERAPEUTICS PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nktr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
